HopeStage
Back to all studies
CompletedNCT04152629

Real-World Safety and Effects of FOQUEST for ADHD

About this titleRead the official source — NCT04152629

Researchers compared Methylphenidate Hydrochloride and Lisdexamfetamine Dimesylate to find out how the approaches affected ADHD symptoms in children with ADHD.

Medication studyAges 6+Canada
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Methylphenidate Hydrochloride and Lisdexamfetamine Dimesylate to find out how the approaches affected ADHD symptoms in children with ADHD.

Who was this study for?

This study was for people with ADHD. Listed age limits: from 6 years. Other eligibility criteria applied.

Listed locations
Calgary and 11 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 19, 2019
Recruitment status
Completed
Enrollment listed in the registry
257
Sponsor
Purdue Pharma, Canada
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
Over 6 Years
Official registry ID
NCT04152629
Official title
Show the full official title

A Phase IV, Real World, Open-label, Multi-centre Study on the Use of FOQUEST® (Methylphenidate Hydrochloride Controlled-release Capsules) for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Pediatric and Adult Patients

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Calgary · Burnaby · Ajax

6 more locations
  • Chatham
  • Etobicoke
  • Greater Sudbury
  • Ottawa
  • Windsor
  • Québec

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Methylphenidate Hydrochloride and Lisdexamfetamine Dimesylate to find out how the approaches affected ADHD symptoms in children with ADHD.

Who is behind this study?

The study sponsor is Purdue Pharma, Canada, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Methylphenidate Hydrochloride and Lisdexamfetamine Dimesylate.

Who was this study for?

This study was for people with ADHD. Listed age limits: from 6 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies